A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Brief description of study

This is a randomized, double-blind, multicenter Phase 3 clinical study. This study plans to enroll about 470 patients, all of whom have advanced non-squamous NSCLC who have progressed on or following EGFR TKI treatment. This study will evaluate the efficacy and safety of AK112 combined with pemetrexed and carboplatin versus placebo combined with pemetrexed and carboplatin in patients with advanced non-squamous NSCLC who progressed on or following EGFR TKI therapy.


Clinical Study Identifier: s23-00889
ClinicalTrials.gov Identifier: NCT05184712
Principal Investigator: Marissa Rybstein.
Other Investigators: Danny Perlaza, Samantha VanMaanen, Elka R Travis, Salman Rafi Punekar, Elaine Shum, Jessica Wang, James Newman, Joshua K Sabari, David Mendoza, Natalia Cherkassky, Vamsidhar Velcheti, Jeffrey G Schneider, Avital Benson, Sally Lau, Melissa L Martinez.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.